EE04616B1 - Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid - Google Patents

Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid

Info

Publication number
EE04616B1
EE04616B1 EEP200000411A EEP200000411A EE04616B1 EE 04616 B1 EE04616 B1 EE 04616B1 EE P200000411 A EEP200000411 A EE P200000411A EE P200000411 A EEP200000411 A EE P200000411A EE 04616 B1 EE04616 B1 EE 04616B1
Authority
EE
Estonia
Prior art keywords
tyrosine kinase
kinase inhibitors
protein tyrosine
heteroaromatic compounds
bicyclic heteroaromatic
Prior art date
Application number
EEP200000411A
Other languages
English (en)
Estonian (et)
Inventor
Clive Carter Malcolm
Stuart Cockerill George
Barry Guntrip Stephen
Elizabeth Lackey Karen
Jane Smith Kathryn
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10825153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04616(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000411A publication Critical patent/EE200000411A/xx
Publication of EE04616B1 publication Critical patent/EE04616B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EEP200000411A 1998-01-12 1999-01-08 Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid EE04616B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800569.7A GB9800569D0 (en) 1998-01-12 1998-01-12 Heterocyclic compounds
PCT/EP1999/000048 WO1999035146A1 (fr) 1998-01-12 1999-01-08 Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase

Publications (2)

Publication Number Publication Date
EE200000411A EE200000411A (et) 2001-12-17
EE04616B1 true EE04616B1 (et) 2006-04-17

Family

ID=10825153

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000411A EE04616B1 (et) 1998-01-12 1999-01-08 Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid

Country Status (47)

Country Link
US (11) US6727256B1 (fr)
EP (3) EP1460072B1 (fr)
JP (2) JP3390741B2 (fr)
KR (1) KR100569776B1 (fr)
CN (1) CN1134438C (fr)
AP (1) AP1446A (fr)
AR (2) AR015507A1 (fr)
AT (3) ATE322491T1 (fr)
AU (2) AU749549C (fr)
BG (1) BG64825B1 (fr)
BR (1) BR9906904B1 (fr)
CA (1) CA2317589C (fr)
CO (1) CO4820390A1 (fr)
CY (3) CY1105618T1 (fr)
CZ (1) CZ298047B6 (fr)
DE (4) DE69918528T2 (fr)
DK (3) DK1454907T3 (fr)
EA (1) EA002455B1 (fr)
EE (1) EE04616B1 (fr)
EG (1) EG24743A (fr)
ES (3) ES2319119T3 (fr)
FR (1) FR08C0038I2 (fr)
GB (1) GB9800569D0 (fr)
GE (1) GEP20022678B (fr)
HR (2) HRP20000469B1 (fr)
HU (1) HU227593B1 (fr)
IL (2) IL137041A0 (fr)
IS (1) IS2276B (fr)
LU (1) LU91475I2 (fr)
MA (1) MA26596A1 (fr)
ME (1) ME00757B (fr)
MY (1) MY124055A (fr)
NL (1) NL300360I2 (fr)
NO (2) NO316176B1 (fr)
NZ (1) NZ505456A (fr)
OA (1) OA11444A (fr)
PE (1) PE20000230A1 (fr)
PL (1) PL192746B1 (fr)
PT (3) PT1460072E (fr)
RS (1) RS49779B (fr)
SI (3) SI1460072T1 (fr)
SK (1) SK285405B6 (fr)
TR (1) TR200002015T2 (fr)
TW (1) TW477788B (fr)
UA (1) UA66827C2 (fr)
WO (1) WO1999035146A1 (fr)
ZA (1) ZA99172B (fr)

Families Citing this family (443)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DK1119567T3 (da) 1998-10-08 2005-07-25 Astrazeneca Ab Quinazolinderivater
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2375259C (fr) 1999-06-21 2009-04-28 Boehringer Ingelheim Pharma Kg Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les preparer
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
JP2003504363A (ja) 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
JP2003520855A (ja) * 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001083432A2 (fr) 2000-05-02 2001-11-08 Array Biopharma, Inc. Procede de reduction de sulfones cyano-substituees en sulfones aminoalkylene-substituees
MXPA02012870A (es) 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
EE200200715A (et) 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EP1792902A1 (fr) * 2000-06-30 2007-06-06 Glaxo Group Limited Procédés pour la préparation de 5-(6-quinazolinyl)-furane-2-carbaldéhydes
IL153111A0 (en) * 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
JP2004505964A (ja) 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ Ｖｅｇｆ阻害活性を有するキノリン誘導体
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
WO2002044166A1 (fr) 2000-11-02 2002-06-06 Astrazeneca Ab Quinolines substituees comme agents antitumoraux
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
EP2796468A2 (fr) 2001-01-05 2014-10-29 Pfizer Inc Anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
EP1512413A3 (fr) * 2001-01-16 2009-09-23 Glaxo Group Limited Composition pharmaceutique contenant de la 4-amino-quinazoline et un autre agent antinéoplastique, pour le traitement du cancer.
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP1377281A4 (fr) * 2001-03-15 2009-06-17 Rhode Island Hospital Composes de taurine
TWI261055B (en) * 2001-03-23 2006-09-01 Bayer Corp Rho-Kinase Inhibitors
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
ATE330956T1 (de) 2001-04-13 2006-07-15 Pfizer Prod Inc Bizyklisch substituierte 4- aminopyridopyrimidinderivate
WO2002092578A1 (fr) * 2001-05-14 2002-11-21 Astrazeneca Ab Derives de quinazoline
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2472619A1 (fr) 2002-01-10 2003-07-24 Bayer Corporation Derives de pyrimidine fusionnes en tant qu'inhibiteurs de la rho-kinase
RS63204A (sr) 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
DK1474420T3 (da) 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
JP4389205B2 (ja) * 2002-02-06 2009-12-24 宇部興産株式会社 ４−アミノキナゾリン化合物の製法
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
AU2003241898A1 (en) * 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7504408B2 (en) 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
AR042461A1 (es) * 2002-12-13 2005-06-22 Neurogen Corp Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas
PL377713A1 (pl) 2002-12-19 2006-02-06 Pfizer Inc. Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
TW200510373A (en) 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
WO2005011607A2 (fr) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Traitement des cancers exprimant p95erbb2
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1660504B1 (fr) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
EP1682123A1 (fr) * 2003-11-07 2006-07-26 SmithKline Beecham (Cork) Limited Methode de traitement du cancer
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1697384B1 (fr) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Derives de pyrido- et pyrimidopyrimidine comme agents anti-proliferation
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
EP1768963A4 (fr) * 2004-06-03 2009-06-10 Smithkline Beecham Cork Ltd Procede de traitement du cancer
US7452887B2 (en) * 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005120512A2 (fr) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Methode de traitement de cancers
US20100226931A1 (en) * 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
WO2006002422A2 (fr) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Composes utilises pour l'immunopotentialisation
WO2006008639A1 (fr) 2004-07-16 2006-01-26 Pfizer Products Inc. Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
WO2006064196A1 (fr) 2004-12-14 2006-06-22 Astrazeneca Ab Composes de pyrazolopyrimidine en tant qu’agents antitumoraux
WO2006066267A2 (fr) * 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Technique de traitement de cancer
WO2006068826A2 (fr) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation Inhibiteurs de la kinase erbb a base de 2-pyrimidinyle pyrazolopyridine
US7812022B2 (en) * 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101103028A (zh) * 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
EP3300739A3 (fr) 2005-03-31 2018-07-18 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
CA2606207C (fr) * 2005-04-19 2014-11-18 Smithkline Beecham (Cork) Limited Preparation pharmaceutique
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
HN2006031275A (es) 2005-09-07 2010-10-29 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
EP1926996B1 (fr) 2005-09-20 2011-11-09 OSI Pharmaceuticals, Inc. Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
US7807673B2 (en) * 2005-12-05 2010-10-05 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ES2329419T3 (es) * 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
EP2010521A1 (fr) 2006-04-19 2009-01-07 Novartis Ag Indazoles et méthodes d'inhibition de cdc7
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
EP2054063A4 (fr) * 2006-08-22 2010-10-27 Concert Pharmaceuticals Inc Dérivés de 4-aminoquinazoline et leurs procédés d'utilisation
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
JP2010505811A (ja) * 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008054633A1 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Dérivés d'hydrazone en tant qu'inhibiteurs de kinase
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
CN102123712B (zh) 2006-12-13 2014-03-19 默沙东公司 使用igf1r抑制剂治疗癌症的方法
EP2125781A2 (fr) 2006-12-20 2009-12-02 Amgen Inc. Hétérocycles substitués et leurs méthodes d'utilisation
ES2449482T3 (es) 2007-01-09 2014-03-19 Amgen Inc. Derivados de bis-aril-amida útiles para el tratamiento de cáncer
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
CN101245050A (zh) 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐
CA2676173A1 (fr) 2007-02-16 2008-08-28 Amgen Inc. Ketones heterocyclyles contenant de l'azote et leur utilisation comme inhibiteurs de c-met
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
AU2008249745B2 (en) * 2007-05-09 2012-01-12 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
WO2008154469A1 (fr) * 2007-06-11 2008-12-18 Smithkline Beecham (Cork) Limited Composés à base de sel de quinazoline
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
MX2010001918A (es) 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
ES2424745T3 (es) 2007-09-07 2013-10-08 Agensys, Inc. Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
JP2011500723A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療
WO2009055343A2 (fr) 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
KR20100087185A (ko) 2007-10-29 2010-08-03 낫코 파마 리미티드 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
CN101492445A (zh) * 2008-01-22 2009-07-29 孙飘扬 杂芳族化合物、其制备方法以及其用途
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
JP2011513370A (ja) * 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2009140144A1 (fr) * 2008-05-15 2009-11-19 Teva Pharmaceutical Industries Ltd. Formes du lapatinib cristallin et leurs procédés de préparation
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
EP2158913A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010027848A2 (fr) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Formes de composés de lapatinib et procédés pour leur préparation
WO2010045495A2 (fr) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anticorps entièrement humains dirigés contre un antigène associé au mélanome de masse moléculaire élevée et leurs utilisations
EP2358666A1 (fr) 2008-11-03 2011-08-24 Natco Pharma Limited Nouveau procédé de préparation de lapatinib et de ses sels de qualité pharmaceutique
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
CN101787017A (zh) * 2009-01-23 2010-07-28 岑均达 光学纯喹唑啉类化合物
CA2748943A1 (fr) 2009-02-09 2010-08-12 Supergen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
WO2010098866A1 (fr) 2009-02-27 2010-09-02 Supergen, Inc. Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US8481503B2 (en) 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
EP2408479A1 (fr) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120386A1 (fr) 2009-04-17 2010-10-21 Nektar Therapeutics Conjugués inhibiteur de protéine tyrosine kinase-oligomère
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
SI2467140T1 (sl) 2009-08-21 2016-10-28 Novartis Ag Lapatinib za zdravljenje raka
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
WO2011039759A1 (fr) * 2009-09-29 2011-04-07 Natco Pharma Limited Nouveau procédé de préparation de lapatinib et de ses sels pharmaceutiquement acceptables
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
CN102079759B (zh) * 2009-12-01 2014-09-17 天津药物研究院 6位取代的喹唑啉类衍生物、其制备方法和用途
WO2011069074A2 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Procédés de traitement de cancer du sein métastasique avec trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
EP2526102B1 (fr) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibiteurs de la PI3 kinase
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
WO2011101644A1 (fr) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de kinases
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (fr) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
CA2793742C (fr) 2010-03-23 2015-06-23 Scinopharm Taiwan Ltd. Procede et intermediaires pour la preparation du lapatinib
US8710221B2 (en) 2010-03-23 2014-04-29 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
WO2011121317A1 (fr) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo[1,2-b][1,2,3]thiadiazoles en tant qu'inhibiteurs de la kinase protéique ou de la kinase lipidique
JP2013526578A (ja) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
US9180129B2 (en) 2010-05-21 2015-11-10 Novartis Ag Combination of lapatinib and trametinib
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
JP2013538042A (ja) 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
WO2011161217A2 (fr) 2010-06-23 2011-12-29 Palacký University in Olomouc Ciblage du vegfr2
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
CN102344444B (zh) * 2010-07-23 2015-07-01 岑均达 光学纯喹唑啉类化合物
CN102344445B (zh) * 2010-07-23 2015-11-25 岑均达 光学纯喹唑啉类化合物
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CA2808236A1 (fr) 2010-08-31 2012-03-08 Genentech, Inc. Biomarqueurs et procedes de traitement
WO2012052948A1 (fr) 2010-10-20 2012-04-26 Pfizer Inc. Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
WO2012052745A1 (fr) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
CN102558159A (zh) * 2010-12-20 2012-07-11 天津药物研究院 4-取代间甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
CN102558160B (zh) * 2010-12-20 2015-09-23 天津药物研究院 4-取代对甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
EP2468883A1 (fr) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Biomarqueurs moléculaires pour la prédiction de la réponse aux inhibiteurs de la tyrosine kinase dans le cancer du poumon
EP2655364A4 (fr) 2010-12-23 2014-06-11 Apotex Pharmachem Inc Procédé pour la préparation de lapatinib et de son sel ditosylate
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
WO2012116040A1 (fr) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
EP2492688A1 (fr) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Biomarqueurs moléculaires pour la prédiction de la réponse à un traitement antitumoral dans le cancer du poumon
KR101940340B1 (ko) 2011-03-04 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 아미노-퀴놀린
AU2012225693A1 (en) 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CA2829219C (fr) 2011-03-09 2021-03-16 Richard G. Pestell Lignees de cellules du cancer de la prostate, signatures geniques et leurs utilisations
EP2685980B1 (fr) 2011-03-17 2017-12-06 The Trustees Of The University Of Pennsylvania Procédés et utilisation de molécules en forme de pince générant une enzyme bifonctionnelle
WO2012125904A1 (fr) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Composés imitant des mutations qui se lient au domaine kinase de l'egfr
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012155339A1 (fr) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 Dérivés de la 4-phénylamino-6-buténamide-7-alkyloxy quinazoline, leur procédé de préparation et leur utilisation
KR101953210B1 (ko) 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
EP2524918A1 (fr) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines en tant qu'inhibiteurs de kinase
ITMI20110894A1 (it) 2011-05-20 2012-11-21 Italiana Sint Spa Impurezza del lapatinib e suoi sali
JP5414739B2 (ja) 2011-05-25 2014-02-12 三菱電機株式会社 半導体テスト治具
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2013005041A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Composés hétérocycliques tricycliques en tant qu'inhibiteurs de kinases
WO2013004984A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés tricycliques pour l'utilisation en tant qu'inhibiteurs de kinase
WO2013005057A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Nouveaux composés
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
US9499530B2 (en) * 2011-08-01 2016-11-22 Hangzhou Minsheng Institutes For Pharma Research Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
WO2013025939A2 (fr) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Composés et méthodes de traitement du cancer par l'inhibition du récepteur de l'urokinase
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013033380A1 (fr) 2011-08-31 2013-03-07 Genentech, Inc. Marqueurs de diagnostic
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
US20130084287A1 (en) 2011-09-30 2013-04-04 Genentech, Inc. Diagnostic markers
AU2011378675B2 (en) 2011-10-04 2017-10-05 Epsilogen Ltd IgE anti -HMW-MAA antibody
BR112014009890A2 (pt) 2011-10-28 2020-10-27 Novartis Ag derivados de purina e seu uso no tratamento de doença
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
WO2013080218A1 (fr) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Nouveaux intermédiaires et procédé de préparation de lapatinib et de ses sels pharmaceutiquement acceptables
KR20140117644A (ko) 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
US9453836B2 (en) 2012-05-14 2016-09-27 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
BR112014028420A2 (pt) 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
WO2013190089A1 (fr) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Biomarqueurs moléculaires permettant de prédire l'issue dans le cancer du poumon
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
WO2014062838A2 (fr) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN102942561A (zh) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-氨基喹唑啉杂环化合物及其用途
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
CN103896889B (zh) * 2012-12-27 2016-05-25 上海创诺制药有限公司 拉帕替尼中间体及其制备方法和应用
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
EP2958552B1 (fr) 2013-02-19 2017-06-21 Hexal AG Composition pharmaceutique comprenant n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine ou un sel pharmaceutiquement acceptable, un solvate ou sel solvaté de celui-ci
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
EP2958592A1 (fr) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Méthodes de traitement du cancer et de prévention de résistance aux médicaments
CN103159747A (zh) * 2013-02-26 2013-06-19 常州鸿创高分子科技有限公司 一种二对甲苯磺酸拉帕替尼的合成方法
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
RU2693480C2 (ru) 2013-03-14 2019-07-03 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
CN105339001A (zh) 2013-03-15 2016-02-17 基因泰克公司 治疗癌症和预防癌症耐药性的方法
WO2014147246A1 (fr) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique pour l'utilisation dans le traitement de maladies hépatiques chroniques associées à une faible expression d'hepcidine
WO2014170910A1 (fr) 2013-04-04 2014-10-23 Natco Pharma Limited Procédé de préparation du lapatinib
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
HU231012B1 (hu) 2013-05-24 2019-11-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Lapatinib sók
CN105705494B (zh) * 2013-07-18 2017-12-15 锦州奥鸿药业有限责任公司 喹唑啉衍生物及其药物组合物，以及作为药物的用途
CA2923667A1 (fr) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Traitement du cancer
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
CN103554091B (zh) * 2013-11-05 2016-05-18 沈阳工业大学 喹唑啉衍生物及其制备方法和用途
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
EP3111222A1 (fr) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2015155624A1 (fr) 2014-04-10 2015-10-15 Pfizer Inc. Dérivés de dihydropyrrolopyrimidine
WO2015156674A2 (fr) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Méthode de traitement du cancer
EP2937346A1 (fr) 2014-04-24 2015-10-28 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Co-cristaux de lapatinib
WO2015166373A1 (fr) 2014-04-30 2015-11-05 Pfizer Inc. Dérivés de dihétérocycle liés à cycloalkyle
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016001789A1 (fr) 2014-06-30 2016-01-07 Pfizer Inc. Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
ES2848857T3 (es) 2014-07-31 2021-08-12 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
US20170252335A1 (en) 2014-10-17 2017-09-07 Novartis Ag Combination of Ceritinib with an EGFR Inhibitor
WO2016100347A2 (fr) * 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Inhibiteurs à petite molécule de l'egfr et de pi3k
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
EP3237638B1 (fr) 2014-12-24 2020-01-15 F.Hoffmann-La Roche Ag Méthodes de traitement, de diagnostic et de pronostic du cancer de la vessie
CN105801565B (zh) * 2014-12-30 2020-04-03 天津法莫西医药科技有限公司 N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[(5-甲酰基)呋喃-2-基]-4-喹唑啉胺制备方法
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
AU2016214923A1 (en) * 2015-02-03 2017-08-24 Trillium Therapeutics Inc. Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
CN106279307B (zh) * 2015-05-19 2019-07-26 正大天晴药业集团股份有限公司 芳氨代葡萄糖衍生物、其制备方法及抗肿瘤用途
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (fr) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Polymorphe de diaryle macrocycle
WO2017009751A1 (fr) 2015-07-15 2017-01-19 Pfizer Inc. Dérivés de pyrimidine
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
RU2759963C2 (ru) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
CA2994925C (fr) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Agent therapeutique pour tumeur
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
CN106632276B (zh) * 2015-10-28 2021-06-15 上海天慈生物谷生物工程有限公司 一种治疗乳腺癌药物的制备方法
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
EP4015537A1 (fr) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Traitements combinés, et utilisations et méthodes associées
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
TW201815799A (zh) 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
CA3036336A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
EP3509423A4 (fr) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
CA3036065A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP6619519B2 (ja) 2016-12-19 2019-12-11 トレロ ファーマシューティカルズ， インコーポレイテッド プロファイリングペプチドおよび感受性プロファイリングのための方法
NZ754994A (en) 2016-12-22 2022-12-23 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019055579A1 (fr) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
WO2019075367A1 (fr) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
EP3727387A4 (fr) 2017-12-18 2021-12-15 Sterngreene, Inc. Composés de pyrimidine utiles en tant qu'inhibiteurs de tyrosine kinase
CN111511746B (zh) 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099118A1 (fr) 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
EP3790886B1 (fr) 2018-05-10 2024-06-26 Amgen Inc. Inhibiteurs du kras g12c pour le traitement du cancer
EP3802535B1 (fr) 2018-06-01 2022-12-14 Amgen, Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099799A1 (fr) 2018-06-11 2019-12-19 Amgen Inc. Inhibiteurs de kras g12c pour le traitement du cancer
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3806887A4 (fr) 2018-06-13 2022-04-06 California Institute of Technology Nanoparticules permettant de traverser la barrière hématoencéphalique et méthodes de traitement faisant appel à celle-ci
BR112020026641A2 (pt) * 2018-06-27 2021-03-30 Oscotec Inc. Derivados de piridopirimidinona para o uso como inibidores de axl
CA3103995A1 (fr) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのｂｄオキシダーゼ阻害剤の発見
WO2020160375A1 (fr) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Polythérapies contre le cancer faisant intervenir de la belantamab mafodotine et un anticorps anti-ox40, utilisations et méthodes associées
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020198077A1 (fr) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
EP3972973A1 (fr) 2019-05-21 2022-03-30 Amgen Inc. Formes à l'état solide
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
ES3051918T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
WO2021026098A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
CN114391012B (zh) 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
WO2021046293A1 (fr) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et du trémélimumab
WO2021043961A1 (fr) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie
EP4048671B1 (fr) 2019-10-24 2026-03-18 Amgen Inc. Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
EP4054719B1 (fr) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Inhibiteurs de ras
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2021097207A1 (fr) 2019-11-14 2021-05-20 Amgen Inc. Synthèse améliorée de composés inhibiteurs de kras g12c
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021108683A1 (fr) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
EP4114530A4 (fr) * 2020-03-02 2024-04-17 Turning Point Therapeutics, Inc. Utilisations thérapeutiques de composés macrocycliques
CA3183032A1 (fr) 2020-06-18 2021-12-23 Mallika Singh Methodes de retardement, de prevention et de traitement de la resistance acquise aux inhibiteurs de ras
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
IL303965A (en) 2020-12-22 2023-08-01 Mekanistic Therapeutics Llc Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (fr) 2022-02-11 2023-08-16 Genzyme Corporation Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
PE20251879A1 (es) 2022-10-14 2025-07-22 Black Diamond Therapeutics Inc Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074057A (en) 1973-12-12 1978-02-14 Takeda Chemical Co., Ltd. 2-Halopropionic acid and its derivatives
US4166735A (en) 1977-01-21 1979-09-04 Shell Oil Company Cycloalkanecarboxanilide derivative herbicides
EP0222839A4 (fr) 1985-05-17 1988-11-09 Univ Australian Composes antipaludiques.
US5141941A (en) 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
BR9101256A (pt) 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993018035A1 (fr) 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
WO1993017682A1 (fr) 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
US5326766A (en) 1992-08-19 1994-07-05 Dreikorn Barry A 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof
DE4308014A1 (de) 1993-03-13 1994-09-15 Hoechst Schering Agrevo Gmbh Kondensierte Stickstoffheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (fr) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
CA2223081C (fr) 1995-06-07 2001-03-06 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
HUP9801177A3 (en) 1995-11-14 1998-11-30 Pharmacia & Upjohn Spa Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
IL153111A0 (en) * 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
DK1474420T3 (da) * 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

Also Published As

Publication number Publication date
JP3390741B2 (ja) 2003-03-31
CY1108859T1 (el) 2014-07-02
IS5549A (is) 2000-06-27
CZ20002587A3 (en) 2001-05-16
EP1454907B1 (fr) 2008-12-17
WO1999035146A1 (fr) 1999-07-15
DE69940128D1 (de) 2009-01-29
HRP20060387A2 (en) 2008-02-29
NL300360I2 (nl) 2009-02-02
US20100120804A1 (en) 2010-05-13
EA002455B1 (ru) 2002-04-25
SI1460072T1 (sl) 2006-08-31
DK1454907T3 (da) 2009-03-09
JP2002500225A (ja) 2002-01-08
DE69918528D1 (de) 2004-08-12
PL192746B1 (pl) 2006-12-29
ES2319119T3 (es) 2009-05-04
HUP0100941A2 (hu) 2001-09-28
PT1047694E (pt) 2004-11-30
US20150065527A1 (en) 2015-03-05
SK285405B6 (sk) 2007-01-04
FR08C0038I2 (fr) 2012-02-22
ES2262087T3 (es) 2006-11-16
CY2008015I2 (el) 2009-11-04
PE20000230A1 (es) 2000-04-03
ATE270670T1 (de) 2004-07-15
PT1460072E (pt) 2006-07-31
EG24743A (en) 2010-07-14
NZ505456A (en) 2003-06-30
US20030176451A1 (en) 2003-09-18
NO316176B1 (no) 2003-12-22
AP2000001861A0 (en) 2000-09-30
AU2010276460A1 (en) 2011-02-17
SI1454907T1 (sl) 2009-04-30
RS49779B (sr) 2008-06-05
CY2008015I1 (el) 2009-11-04
EP1460072A1 (fr) 2004-09-22
US7109333B2 (en) 2006-09-19
BR9906904B1 (pt) 2011-05-03
CZ298047B6 (cs) 2007-06-06
EP1047694A1 (fr) 2000-11-02
UA66827C2 (uk) 2004-06-15
SI1047694T1 (en) 2005-02-28
PL341595A1 (en) 2001-04-23
YU44800A (sh) 2002-11-15
TW477788B (en) 2002-03-01
AP1446A (en) 2005-07-19
GB9800569D0 (en) 1998-03-11
AU749549C (en) 2003-03-20
EP1460072B1 (fr) 2006-04-05
JP2002326990A (ja) 2002-11-15
NO20003561L (no) 2000-09-11
DE69930773D1 (de) 2006-05-18
ATE322491T1 (de) 2006-04-15
OA11444A (en) 2004-04-29
NO20003561D0 (no) 2000-07-11
ATE417847T1 (de) 2009-01-15
ES2221354T3 (es) 2004-12-16
CA2317589A1 (fr) 1999-07-15
US6727256B1 (en) 2004-04-27
MA26596A1 (fr) 2004-12-20
US20160339027A1 (en) 2016-11-24
DE69918528T2 (de) 2005-07-28
HRP20000469A2 (en) 2001-06-30
US6713485B2 (en) 2004-03-30
AR015507A1 (es) 2001-05-02
CA2317589C (fr) 2007-08-07
DE69930773T2 (de) 2006-09-28
US8912205B2 (en) 2014-12-16
LU91475I2 (fr) 2008-11-10
AU2278399A (en) 1999-07-26
FR08C0038I1 (fr) 2008-11-14
EA200000637A1 (ru) 2001-02-26
BG104668A (en) 2001-04-30
KR20010015902A (ko) 2001-02-26
ZA99172B (en) 2000-07-11
US20070238875A1 (en) 2007-10-11
HU227593B1 (en) 2011-09-28
US20160051551A1 (en) 2016-02-25
EP1454907A1 (fr) 2004-09-08
HK1031883A1 (en) 2001-06-29
EP1047694B1 (fr) 2004-07-07
IL137041A0 (en) 2001-06-14
LU91475I9 (fr) 2019-01-02
US8513262B2 (en) 2013-08-20
CN1292788A (zh) 2001-04-25
EE200000411A (et) 2001-12-17
CO4820390A1 (es) 1999-07-28
ME00757B (me) 2008-06-05
NL300360I1 (nl) 2008-11-03
SK10502000A3 (sk) 2001-08-06
US9199973B2 (en) 2015-12-01
BG64825B1 (bg) 2006-05-31
CN1134438C (zh) 2004-01-14
CY1105618T1 (el) 2010-12-22
IL137041A (en) 2006-10-05
AR066982A2 (es) 2009-09-23
NO2008017I1 (no) 2008-12-01
HRP20000469B1 (hr) 2007-05-31
IS2276B (is) 2007-09-15
US20130310562A1 (en) 2013-11-21
GEP20022678B (en) 2002-04-25
TR200002015T2 (tr) 2001-01-22
US20050130996A1 (en) 2005-06-16
MY124055A (en) 2006-06-30
DE122008000048I1 (de) 2009-01-02
DK1047694T3 (da) 2004-11-08
AU749549B2 (en) 2002-06-27
BR9906904A (pt) 2000-10-17
HUP0100941A3 (en) 2002-09-30
PT1454907E (pt) 2009-02-18
KR100569776B1 (ko) 2006-04-11
DK1460072T3 (da) 2006-07-31
US20020147205A1 (en) 2002-10-10
US20070015775A1 (en) 2007-01-18
NO2008017I2 (fr) 2011-10-17

Similar Documents

Publication Publication Date Title
EE04616B1 (et) Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
ATE255575T1 (de) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
EE05432B1 (et) Prroloprimidiinid kui valgukinaasi inhibiitorid

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

AA1Y Spc filed

Free format text: PRODUCT NAME: TYVERB-LAPATINIB; REGISTRATION NO/DATE: C(2008)2742 20080610

Spc suppl protection certif: C20080005

Filing date: 20081120

FG1Y Spc granted

Free format text: PRODUCT NAME: TYVERB-LAPATINIB; REGISTRATION NO/DATE: C(2008)2742 20080610

Spc suppl protection certif: 00020 C20080005

Filing date: 20081120

Free format text: PRODUCT NAME: TYVERB-LAPATINIB

Spc suppl protection certif: C20080005 00020

Filing date: 20081120

Extension date: 20230612

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner